MANNKIND CORP(MNKD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,238 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
MNKD Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for MANNKIND CORP (MNKD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MNKD at 37.2/100 on a 32-signal composite quality model, placing it at rank #2,238 of 2,962 stocks — the bottom half of the AI-ranked universe. MNKD scores in the top quartile across revenue growth (87.1). Areas of concern include profitability (17.3) and institutional flow (19.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MANNKIND CORP reports quarterly revenue of $109.4M, net income of $-19.0M, an operating margin of -0.3%. Top institutional holders of MNKD by reported 13-F value include BlackRock, Rubric Capital Management, STATE STREET, based on the most recent SEC filings. MNKD trades on the Nasdaq exchange and files with the SEC under CIK 899460. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MNKD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MANNKIND CORP directly from SEC EDGAR. MANNKIND CORP's 13F Pro composite quality score has ranged between 23 and 68 since 2021, currently 37.2 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$109.4M
Net Income
Q2 2026
$-19.0M
Free Cash Flow
Q2 2026
$-23.5M
Operating Margin
Q2 2026
-0.3%
ROIC
Q2 2026
-0.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+22.2% YoYNet Income
-78.7% YoYOperating Income
-46.5% YoYEPS (Diluted)
-80.0% YoYTotal Assets
+101.1% YoYTotal Debt
+883.7% YoYOp. Cash Flow
-57.1% YoYFree Cash Flow
-58.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $349.0M +22.2% | $285.5M +43.5% | $199.0M +99.4% | $99.8M +32.2% | $75.4M +15.8% | $65.1M |
| Net Income | $5.9M -78.7% | $27.6M +331.1% | $-11.9M +86.3% | $-87.4M -8.0% | $-80.9M -41.4% | $-57.2M |
| Operating Income | $38.8M -46.5% | $72.6M +736.4% | $8.7M +113.5% | $-64.1M -36.3% | $-47.0M +1.9% | $-47.9M |
| EPS (Diluted) | $0.02 -80.0% | $0.10 +350.0% | $-0.04 +88.2% | $-0.34 -6.3% | $-0.32 -23.1% | $-0.26 |
| Total Assets | $792.2M +101.1% | $393.8M -17.1% | $475.2M +60.9% | $295.3M -8.1% | $321.2M +195.7% | $108.6M |
| Total Debt | $354.6M +883.7% | $36.1M -86.6% | $268.7M -1.8% | $273.5M -2.7% | $281.2M +130.1% | $122.2M |
| Operating Cash Flow | $18.3M -57.1% | $42.5M +24.7% | $34.1M +142.3% | $-80.7M -30.7% | $-61.7M -119.4% | $-28.1M |
| Free Cash Flow | $13.7M -58.3% | $32.8M +493.2% | $-8.3M +90.5% | $-88.3M -20.6% | $-73.2M -152.9% | $-28.9M |
Get alerted when MNKD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MANNKIND CORP including:
Top Institutional Holders of MNKD
BlackRock, Inc.
$136.9M32,133,223 shRubric Capital Management LP
$76.7M18,000,000 shSTATE STREET CORP
$68.9M16,174,043 shVANGUARD CAPITAL MANAGEMENT LLC
$56.1M13,169,392 shGEODE CAPITAL MANAGEMENT, LLC
$33.9M7,947,203 shWELLINGTON MANAGEMENT GROUP LLP
$33.4M7,844,807 shFrazier Life Sciences Management, L.P.
$28.1M6,600,000 shDeep Track Capital, LP
$25.6M6,000,000 sh180 WEALTH ADVISORS, LLC
$21.1M4,959,351 shFMR LLC
$17.5M4,101,046 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $136.9M | 32,133,223 |
| Rubric Capital Management LP | $76.7M | 18,000,000 |
| STATE STREET CORP | $68.9M | 16,174,043 |
| VANGUARD CAPITAL MANAGEMENT LLC | $56.1M | 13,169,392 |
| GEODE CAPITAL MANAGEMENT, LLC | $33.9M | 7,947,203 |
| WELLINGTON MANAGEMENT GROUP LLP | $33.4M | 7,844,807 |
| Frazier Life Sciences Management, L.P. | $28.1M | 6,600,000 |
| Deep Track Capital, LP | $25.6M | 6,000,000 |
| 180 WEALTH ADVISORS, LLC | $21.1M | 4,959,351 |
| FMR LLC | $17.5M | 4,101,046 |
Companies Similar to MNKD
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Immunocore Holdings plc
Evolus, Inc.
ARDELYX, INC.
CERUS CORP
ORTHOPEDIATRICS CORP
Alphatec Holdings, Inc.
Schrodinger, Inc.
GeneDx Holdings Corp.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put MNKD on your watchlist
Track score changes the day MANNKIND CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MNKD a good stock to buy?
13F Pro's AI-powered analysis of MANNKIND CORP (MNKD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MNKD are available on the MNKD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MNKD is classified as a small company.
Which hedge funds own MNKD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MNKD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MANNKIND CORP's investment landscape.